logo

Axsome Therapeutics, Inc. (AXSM)



Trade AXSM now with
  Date
  Headline
12/10/2018 7:07:31 AM Axsome : IDMC Recommends Continuation Of Trial Evaluating AXS-05 Versus Placebo In Alzheimer’s Disease Agitation
11/14/2018 7:10:37 AM Axsome Therapeutics Completes Patient Enrollment In ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder
11/9/2018 7:09:19 AM Axsome Therapeutics Q3 Net Loss $8.3 Mln Or $0.31/Shr Vs Net Loss Of $6.4 Mln Or $0.27/Shr Last Year
10/17/2018 7:03:23 AM Axsome Therapeutics Receives Orphan Drug Designation From FDA For AXS-12 For Treatment Of Narcolepsy
10/16/2018 7:09:26 AM Axsome Therapeutics Announces Next CNS Product Candidate, AXS-12 For Narcolepsy Treatment
10/11/2018 7:16:52 AM Axsome Therapeutics To Focus On Growing Core CNS Portfolio
9/28/2018 7:09:20 AM Axsome Therapeutics Unveils $8.9 Mln Registered Direct Offering
8/8/2018 7:06:51 AM Axsome Therapeutics Q2 Net Loss $8.3 Mln Or $0.32/Shr Vs Loss Of $7.1 Mln Or $0.30/Shr Last Year
7/17/2018 7:04:28 AM Axsome Therapeutics Announces AXS-05 Presentation
6/5/2018 7:05:10 AM Axsome Therapeutics Initiates Phase 2 Trial Of AXS-05 In Major Depressive Disorder
5/8/2018 7:16:02 AM Axsome Therapeutics Q1 Net Loss $4.8 Mln Or $0.19/Shr Vs Loss Of $8.0 Mln Or $0.41/Shr Last Year
4/23/2018 7:04:33 AM Axsome Therapeutics Says First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation
4/19/2018 7:08:00 AM Axsome Therapeutics Names Nick Pizzie CFO, Effective May 16